It's been 17 years since my diagnosis of stage 3a non–small cell lung cancer. I can remember that moment as if it was yesterday.
An Extraordinary Healer essay honoring Debbie O’Sullivan, RN, OCN [UT Health Northeast Cancer Treatment and Prevention Center in Tyler, Texas]
Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.
A prostate cancer survivor offers his thoughts on what you should (and shouldn't) say to someone who was recently diagnosed.
An essay honoring SARA SARGENTE, RN, OCN [ORANGE REGIONAL MEDICAL CENTER, MIDDLETOWN, NEW YORK]
"I don’t have cancer, but here I am. This is my life. This is my reality. I am BRCA positive."
Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone.
I didn’t like thinking of myself as a “survivor.” There was something … I don’t know. Something a little shameful, maybe, about it.
Navigating the emotional and practical hurdles of caring for parents and stepparents.
An Extraordinary Healer essay honoring Sharon Bird, BSN, RN [ THOMAS JEFFERSON UNIVERSITY HOSPITAL IN RADNOR, PENNSYLVANIA ]
Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.
As the treatment paradigm shifts for triple-negative breast cancer, PARP inhibitors will continue to play a role.
Going in for an infusion amid the coronavirus pandemic with a possible "symptom" of COVID-19 and wondering what risks lie ahead.
Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.
Kay Verble discusses a research endeavor to characterize long-term survivors of glioblastoma multiforme (GBM).
Eric Stonestreet, our 2016 Extraordinary Healers Guest Speaker, discusses why he lends his name and fame to cancer advocacy.
Techniques open a field of opportunity for stem cell transplant recipients.